Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients

References

• Raman VS, Heptulla RA. New potential adjuncts to treatment of children with type 1. Pediatr Res. 2009 Apr;65(4):370–374.
   PubMed Web of Science ®Google Scholar
• Gao YQ, Gao M, Xue Y. Treatment of diabetes in children (Review). Exp Ther Med. 2016 Apr;11(4):1168–1172.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Guglielmi C. Double diabetes: a mixture of type 1 and type 2 diabetes in youth. Endocr Dev. 2009;14:151–166.
   PubMedGoogle Scholar
• Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr. 1994;125:177–188.
   PubMed Web of Science ®Google Scholar
• Bacha F, Klinepeter Bartz S. Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes. Pediatr Diabetes. 2016 Dec;17:545–558.
   PubMed Web of Science ®Google Scholar
• Wherrett DK, Chiang JL, Delamater AM, et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015;38:1975–1985.
   PubMed Web of Science ®Google Scholar
• Bode BW, Garg SK. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract. 2016 Feb;22:220–230.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40:Suppl 1.
   Web of Science ®Google Scholar
• Jefferies CA, Hamilton JDD. Potential adjunctive therapies in adolescents with type 1 diabetes mellitus. Treat Endocrinol. 2004;3:337–343.
   PubMedGoogle Scholar
• Lyons SK, Hermann JM, Miller KM, et al. Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the prospective diabetes follow-up and T1D exchange registries. Diabetes Care. 2017 Oct;40:e139–e140.
   PubMed Web of Science ®Google Scholar
• Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–496.
   PubMed Web of Science ®Google Scholar
• Biester T, Kordonouri O, Danne T. Pharmacological properties of faster-acting insulin aspart. Curr Diab Rep. 2017 Sep 23;17:101.
   PubMed Web of Science ®Google Scholar
• Aathira R, Jain V. Advances in management of type 1 diabetes mellitus. World J Diabetes. 2014 Oct 15;5:689–696.
   PubMedGoogle Scholar
• Maurizi AR, Suraci C, Pitocco D, et al. Position statement on the management of continuous subcutaneous insulin infusion (CSII): the Italian Lazio experience. J Diabetes. 2016 Jan;8:41–44.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Crinò A, Schiaffini R, et al. A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). Diabetes Technol Ther. 2003;5:965–974.
   PubMedGoogle Scholar
• DeBoer MD, Breton MD, Wakeman C, et al. Performance of an artificial pancreas system for young children with type 1 diabetes. Diabetes Technol Ther. 2017;19:293–298.
   PubMed Web of Science ®Google Scholar
• Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017 Mar;19:155–163.
   PubMed Web of Science ®Google Scholar
• Anderson J, Peña AS, Sullivan T, et al. Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial. BMC Pediatr. 2013 Jul 16;13:108.
   PubMed Web of Science ®Google Scholar
• Brufani C, Fintini D, Nobili V, et al. Use of metformin in pediatric age. Pediatr Diabetes. 2011;12:580–588.
   PubMed Web of Science ®Google Scholar
• Ferguson AW, De La Harpe PL, Farquhar JW. Dimethyldiguanide in the treatment of diabetic children. Lancet. 1961 Jun 24;1:1367–1369.
   PubMed Web of Science ®Google Scholar
• Gómez R, Mokhashi MH, Rao J, et al. Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. J Pediatr Endocrinol Metab. 2002;15:1147–1151.
   PubMed Web of Science ®Google Scholar
• Urakami T, Morimoto S, Owada M, et al. Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus. Pediatr Int. 2005;47:430–433.
   PubMed Web of Science ®Google Scholar
• Konrad K, Datz N, Engelsberger I, et al. Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria. Pediatr Diabetes. 2015;16:529–537.
   PubMed Web of Science ®Google Scholar
• Hamilton J, Cummings E, Zdravkovic V, et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care. 2003;26:138–143.
   PubMed Web of Science ®Google Scholar
• Särnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003 Oct;149:323–329.
   PubMed Web of Science ®Google Scholar
• Nadeau KJ, Chow K, Alam S, et al. Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. Pediatr Diabetes. 2015 May;16:196–203.
   PubMed Web of Science ®Google Scholar
• Libman IM, Miller KM, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015 Dec 1;314:2241–2250.
   PubMed Web of Science ®Google Scholar
• Schauer IE, Snell-Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes. 2011;60:306–314.
   PubMed Web of Science ®Google Scholar
• Bergman BC, Howard D, Schauer IE, et al. The importance of palmitoleic acid to adipocyte insulin resistance and whole-body insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab. 2013;98:E40–50.
   PubMed Web of Science ®Google Scholar
• Szadkowska A, Pietrzak I, Mianowska B, et al. Insulin sensitivity in type 1 diabetic children and adolescents. Diabet Med. 2008;25:282–288.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990 Jun;13:610–630.
   PubMed Web of Science ®Google Scholar
• Łuczyński W, Głowińska-Olszewska B, Bossowski A. The influence of clinical and genetic factors on the development of obesity in children with type 1 diabetes. Diabetes Metab Res Rev. 2016 Oct;32:666–671.
   PubMed Web of Science ®Google Scholar
• Raab J, Haupt F, Kordonouri O, et al. Continuous rise of insulin resistance before and after the onset of puberty in children at increased risk for type 1 diabetes - a cross-sectional analysis. Diabetes Metab Res Rev. 2013;29:631–635.
   PubMed Web of Science ®Google Scholar
• Clayton KL, Holly JM, Carlsson LM, et al. Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf). 1994;41:517–524.
   PubMed Web of Science ®Google Scholar
• Al Khalifah RA, Alnhdi A, Alghar H, et al. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: a systematic review and meta-analysis. Pediatr Diabetes. 2017;18:664–673.
   PubMed Web of Science ®Google Scholar
• Pitocco D, Zaccardi F, Tarzia P, et al. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. Diabetes Obes Metab. 2013;15:427–431.
   PubMed Web of Science ®Google Scholar
• Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept. 2005 Jun 15;128:117–124.
   PubMed Web of Science ®Google Scholar
• Lugari R, Dell’Anna C, Ugolotti D, et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res. 2000;32:424–428.
   PubMed Web of Science ®Google Scholar
• Huml M, Kobr J, Siala K, et al. Gut peptide hormones and pediatric type 1 diabetes mellitus. Physiol Res. 2011;60:647–658.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706–2713.
   PubMed Web of Science ®Google Scholar
• Wood JR, Silverstein J. Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth. Curr Opin Pediatr. 2013 Aug;25:502–508.
   PubMed Web of Science ®Google Scholar
• Kelly AS, Metzig AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring). 2012;20:364–370.
   PubMed Web of Science ®Google Scholar
• Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013;167:355–360.
   PubMed Web of Science ®Google Scholar
• Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010 Jun;33:1294–1296.
   PubMed Web of Science ®Google Scholar
• Renukuntla VS, Ramchandani N, Trast J, et al. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J Diabetes Sci Technol. 2014 Sep;8:1011–1017.
   PubMedGoogle Scholar
• Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77–84.
   PubMed Web of Science ®Google Scholar
• Mader JK, Jensen L, Ingwersen SH, et al. Pharmacokinetic properties of liraglutide as adjunct to insulin in subjects with type 1 diabetes mellitus. Clin Pharmacokinet. 2016;55:1457–1463.
   PubMed Web of Science ®Google Scholar
• Agersø H, Jensen LB, Elbrønd B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195–202.
   PubMed Web of Science ®Google Scholar
• Elbrønd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002;25:1398–1404.
   PubMed Web of Science ®Google Scholar
• Damholt B, Golor G, Wierich W, et al. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006;46:635–641.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Battelino T, Chatterjee DJ, et al. Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther. 2014;16:679–687.
   PubMed Web of Science ®Google Scholar
• Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2004 Jan;53:250–264.
   PubMedGoogle Scholar
• Cernea S, Raz I, Herold KC, et al. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev. 2009;25:694–704.
   PubMed Web of Science ®Google Scholar
• Ludvigsson J. C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res Rev. 2009 Nov;25:691–693.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med. 1998 Apr 1;128:517–523.
   PubMed Web of Science ®Google Scholar
• Barker A, Lauria A, Schloot N, et al. Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab. 2014;16:262–267.
   PubMed Web of Science ®Google Scholar
• Hao W, Gitelman S, DiMeglio LA, et al. Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to Age, HbA1c, and insulin dose. Diabetes Care. 2016;39:1664–1670.
   PubMed Web of Science ®Google Scholar
• Lauria A, Barker A, Schloot N, et al. BMI is an important driver of β-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children. Eur J Endocrinol. 2015;172:107–113.
   PubMed Web of Science ®Google Scholar
• Ehlers MR. Immune interventions to preserve β cell function in type 1 diabetes. J Investig Med. 2016 Jan;64:7–13.
   PubMed Web of Science ®Google Scholar
• Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014 Jan;63:9–19.
   PubMed Web of Science ®Google Scholar
• Griffin KJ, Thompson PA, Gottschalk M, et al. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2:710–718.
   PubMed Web of Science ®Google Scholar
• Lapuerta P, Zambrowicz B, Strumph P, et al. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res. 2015;12:101–110.
   PubMed Web of Science ®Google Scholar
• Cheng ST, Chen L, Li SY, et al. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes. PLoS One. 2016 Jan 25;11:e0147391.
   PubMed Web of Science ®Google Scholar
• Luippold G, Klein T, Mark M, et al. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab. 2012;14:601–607.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014 May 4;5:265–275.
   PubMed Web of Science ®Google Scholar
• Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014 Jun;23:875–882.
   PubMed Web of Science ®Google Scholar
• Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66:975–987.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014 Jan 29;13:28.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480–1483.
   PubMed Web of Science ®Google Scholar
• Biester T, Aschemeier B, Fath M, et al. Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. Diabetes Obes Metab. 2017;19:1635–1639.
   PubMed Web of Science ®Google Scholar
• Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412–419.
   PubMed Web of Science ®Google Scholar
• Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38:2258–2265.
   PubMed Web of Science ®Google Scholar
• Tamez HE, Tamez AL, Garza LA, et al. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 2015 Oct 9;14:78.
   PubMed Web of Science ®Google Scholar
• Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015 Jul;38:1181–1188.
   PubMed Web of Science ®Google Scholar
• Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017 Sep 13;377:2337–2348.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000 Aug;106:453–458.
   PubMed Web of Science ®Google Scholar
• Lawrence JM, Yi-Frazier JP, Black MH, et al.; SEARCH for Diabetes in Youth Study Group. Demographic and clinical correlates of diabetes-related quality of life among youth with type 1 diabetes. J Pediatr. 2012;161:201–207.e2.
   PubMed Web of Science ®Google Scholar
• Naughton MJ, Ruggiero AM, Lawrence JM, et al.; SEARCH for Diabetes in Youth Study Group. Health-related quality of life of children and adolescents with type 1 or type 2 diabetes mellitus: SEARCH for diabetes in youth study. Arch Pediatr Adolesc Med. 2008;162:649–657.
   PubMedGoogle Scholar